1Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L.Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990, 12: 415-6.
2Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T.Oxidative metabolism of omeprazole in human liver microsomes:cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 1993; 266: 52-9.
3Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al. CYP2CI9 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66.
4Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al. CYP2CI9 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18: 721-7.
5Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M,et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2CI9 genetic polymorphism. Aliment Pharmacol Ther 2001 ; 15: 1479-84.
6Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, et al. A randomized open trial for comparison of protonpump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2CI9 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-8.
7Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 2000; 21:193-9.
8de Morals SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-11.
9Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor,in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 32:466-73.
10Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, et al. Comparison of interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther 1995; 58: 155-64.
1Chung IK, Lee DH, Kim HU, et al. Guidelines of treatment for bleeding peptic ulcer disease. Korean J Gastroenterol, 2009, 54: 298-305.
2Tsibouris P, Zintzaras E, Lappas C, et al. High-dose pantoprazole continuous infusion is superior to soma- tostatin after endoscopic hemostasis in patients with pep- tic ulcer bleeding. Am J Gastroenterol, 2007, 102 : 1192-1199.
3Mostaghni AA, Hashemi SA, Heydari ST. Comparison of oral and intravenous proton pump inhibitor on patients with high risk bleeding peptic ulcers: a prospective, randomized, controlled clinical trial. Iran Red Crescent MedJ, 2011, 13: 458-463.
5Miner PJ, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, panto- prazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol, 2003, 98: 2616-2620.
6Wedemeyer RS, Blume H. Pharmacokinetie drug inter- action profiles of proton pump inhibitors: an update. Drug Saf, 2014, 37: 201-211.
7Janha RE, Worwui A, Linton K J, et al. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution. BMC Evol Biol, 2014, 14: 71.
8He N, Yan FX, Huang SL, et al. CYP2C19 genotypeand S-mephenytoin 4'-hydroxylation phenotype in a Chi- nese Dai population. Eur J Clin Pharmaeol, 2002, 58 : 15-18.
9RomOn M, Oehoa D, Stnchez-Rojas SD, et al. Evalua- tion of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pan- toprazole and rabeprazole. Pharmaeogenomies, 2014, 15 : 1893-1901.
10van Rensburg C J, Cheer S. Pantoprazole for the treat- ment of peptic ulcer bleeding and prevention of rebleed- ing. Clin Med Insights Gastroenterol, 2012, 5: 51-60.
